Bavarian Nordic A/S (OTCMKTS:BVNRY) Announces Earnings Results, Beats Estimates By $0.07 EPS

Bavarian Nordic A/S (OTCMKTS:BVNRY) announced its quarterly earnings data on Wednesday. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.40 by $0.07, Zacks reports. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%.

Bavarian Nordic A/S Trading Down 0.5 %

OTCMKTS BVNRY opened at $7.68 on Wednesday. The stock has a market cap of $1.82 billion, a PE ratio of 11.13 and a beta of 1.68. Bavarian Nordic A/S has a 12 month low of $6.86 and a 12 month high of $14.60. The company’s 50-day moving average price is $8.56 and its 200-day moving average price is $9.94.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.